Psych Capital PLC Result of AGM (8210H)
28 Novembre 2022 - 3:43PM
UK Regulatory
TIDMPSY
RNS Number : 8210H
Psych Capital PLC
28 November 2022
Psych Capital Plc
("Psych Capital" or the "Company")
Result of Annual General Meeting
28 November 2022
The Board of Psych Capital is pleased to announce that at its
2022 Annual General Meeting ("AGM") held today, all resolutions
were duly passed.
The Directors of the Company accept responsibility for the
contents of this announcement.
For further information, please contact:
Psych Capital Plc
Stephen Murphy, Executive Director
Will Potts, Chief Investment Officer
info@PSYCH.capital
AQSE Growth Market Corporate Adviser
Peterhouse Capital Limited
Tel: +44 (0) 207 469 0930
Guy Miller / Mark Anwyl
About Psych Capital Plc
Psych Capital Plc identifies, funds and aims to support the
building of British and European companies across three core
pillars: therapeutic treatments, drug development, and data/AI. Its
mission is to support a new wave of innovators who are well
positioned to challenge the status-quo and revolutionise how
society deals with mental health conditions.
Through a network of analysts with deep industry knowledge and
capital markets expertise, Psych Capital is focussed on developing
a rigorously selected portfolio of industry leading companies at
the intersection of psychedelic medicine and technology.
The Psych Platform is a business-to-business media and content
platform for the psychedelic science and healthcare industry, and
it operates the website, https://psych.global/. The Psych Platform
is a global B2B resource for networking, intelligence and insights,
servicing the industry through publications, newsletters and
engaging events. The Psych Platform has amassed a significant
global B2B audience, with over 20,000 subscribers to the
platform.
As a business-to-business media and content platform, the Psych
Platform also produces the PSYCH Symposium, a premium Live Event
series.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXBPBITMTITBBT
(END) Dow Jones Newswires
November 28, 2022 09:43 ET (14:43 GMT)
Grafico Azioni Shortwave Life Sciences (AQSE:PSY)
Storico
Da Gen 2025 a Feb 2025
Grafico Azioni Shortwave Life Sciences (AQSE:PSY)
Storico
Da Feb 2024 a Feb 2025
